← Eichor
Study identifier: NCT05814432 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Efficacy and Safety of High-dose Liposomal Amphotericin B for Disseminated Histoplasmosis in AIDS

Condition: Disseminated Histoplasma Capsulatum Infection · AIDS and Infections · Immunosuppression  ·  Sponsor: Federal University of Health Science of Porto Alegre

PhasePhase 3
Planned participants279
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Phase III trial evaluating the safety and efficacy of a single high dose (10 mg/kg) of liposomal amphotericin B for disseminated histoplasmosis in AIDS patients, in comparison to standard therapy (3 mg/kg of liposomal amphotericin B for two weeks) (INDUCTION trial).

This description comes directly from the study's public registry record.

Talk to the study team

Alessandro C Pasqualotto, MD PhD  ·  +5551999951614  ·  acpasqualotto@hotmail.com

Diego R Falci, MD PhD  ·  +5551997507835  ·  diego.falci@gmail.com

Always discuss trial participation with your own doctor first.

Locations (5)

Hospital de Doenças TropicaisGoiânia, Goiás, BrazilRecruiting
Hospital Giselda TrigueiroNatal, Rio Grande do Norte, BrazilRecruiting
Federal University of Health Sciences of Porto AlegrePorto Alegre, Rio Grande do Sul, BrazilRecruiting
Hospital de Clinicas de Porto AlegrePorto Alegre, Rio Grande do Sul, BrazilRecruiting
Hospital Geral de RoraimaBoa Vista, Roraima, BrazilRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05814432